Recursion Announces Board Transition

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson ...

Recursion Pharmaceuticals May Be Losing Ground To Its Peers

Recursion Pharmaceuticals' AI-driven Recursion OS platform shows strong potential but has yet to demonstrate a clear ...
Nasdaq

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets ...
AOL

Is Recursion Pharmaceuticals a Meme Stock?

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BSTSalt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...
The Motley Fool

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...